Список литературы
Титов В.Н. Биологическая функция трофологии (питания) и патогенез метаболического синдрома — физиологичного переедания. Филогенетическая теория общей патологии, лептин и адипонектин. Патологическая физиология и экспериментальная терапия. 2014; 2: 68 — 79.
Титов В.Н., Амелюшкина В.А., Рожкова Т.А. Конформация апоВ-100 в филогенетически и функционально разных липопротеинах низкой и очень низкой плотности. Алгоритм формирования фенотипов гиперлипопротеинемии. Клиническая лабораторная диагностика. 2014; 1: 27-38.
Mahalle N., Kulkarni M.V., Naik S.S., Garg M.K. Association of dietary factors with insulin resistance and inflammatory markers in subjects with diabetes mellitus and coronary artery disease in Indian population. J. Diabetes. Complications. 2014 Jul-Aug;28(4):536.
Kinoshita M., Kojima M., Matsushima T., Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin. Chim. Acta. 2005 Jan;351(1-2):115-20.
Ramasamy I., Update on the molecular biology of dyslipidemias. Clin. Chim. Acta. 2016;.454:.143 — 185.
Battula S.B., Fitzsimons Oю, Moreno Sю, Owens Dю, Collins P, Johnson Aю, Tomkin GюH. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism? Metabolism. 2000; 49(8): 1049 — 54.
Zheng C., Khoo C, Furtado J, Ikewaki K, Sacks FM. Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. Am J Clin Nutr. 2008 Aug;88(2):272-81.
Drouin-Chatier J.P., Hogue J.C., Tremblay A.J., Bergeron J., Lamarche B., Couture P. The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels. Lipids. Health. Dis. 2017; 16(1): 119 — 26.
März W, Grammer T.B., Delgado G., Kleber M.E. Congenital disorders of lipoprotein metabolism. Herz. 2017; 42(5): 449 — 58.
Lewis G.F., Xiao C., Hegele R.A. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr. Rev. 2015; 36(1): 131 — 47.
Титов В.Н., Лисицын Д.М. Жирные кислоты. Физическая химия, биология и медицина. М.- Тверь: ООО «Издательство «Триада». 2006
Sahin N., Akoh C.C., Karaali A. Lipase-catalyzed acidolysis of tripalmitin with hazelnut oil fatty acids and stearic acid to produce human milk fat substitutes. J. Agric. Food. Chem. 2005; 53(14): 5779 — 83
Титов В.Н. Первичный и вторичный атеросклероз, атероматоз и атеротромбоз. М.- Тверь: ООО «Издательство «Триада»; 2008.
Рожкова Т.А., Титов В.Н., Амелюшкина В.А, Каба С.И., Кухарчук В.В. Липолиз в филогенетически ранних липопротеинах низкой плотности и более поздних липопротеинах очень низкой плотности; функция и диагностическое значение апоЕ и апоС-III. Клиническая лабораторная диагностика. 2015; 60(12): 4 — 14.
Gaudet D., Alexander V.J., Baker B.F., Brisson D., Tremblay K. Antisense Inhibition of фpolipoprotein C-III in зatients with рypertriglyceridemia. N. Engl. J. Med. 2015; 373(5): 438 — 47.
Yamamot M., Yamamot M1, Oohashi T, Katoh N, Oikawa S. Increased serum concentration of apolipoprotein C-III and its greater distribution to chylomicrons than to the high-density lipoprotein fraction in a calf with hyperlipidemia. J Vet Med Sci. 2000 Oct;62(10):1033-9.
Takahashi T., Hirano T., Okada K., Adachi M. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice. Metabolism. 2003; 52(10): 1354 — 9.
Gordts P., Nock R., Son N.H., Ramms B., Lew I., Gonzales J.C. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J. Clin. Invest. 2016; 126(8): 2855 — 66.
Klein R.L., McHenry M.B., Lok K.H., Hunter S.J., Le N.A., Jenkins A.J., Zheng D., Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004; 53(10): 1296 — 1304.
Ai M., Otokozawa S., Asztalos B.F., Ito Y., Nakajima K., White C.C., Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin. Chem. 2010; 56(6): 967 — 76.
Olivieri O., Martinelli N., Girelli D., Pizzolo F., Friso S, Beltrame F. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J. Thromb. Haemost. 2010; 8(3): 463 — 71.
Hiukka A., Fruchart-Najib J., Leinonen E., Hilden H., Fruchart J.C., Taskinen M.R. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia. 2005; 48(6): 1207 — 15.
Ikeda H., Ikeda T. The ratios of apoC-III/apoC-II in normal full-term maternal bloods and their umbilical cord bloods. Rinsho Byori. 2001; 49(1): 45 — 50.
Larsson M., Vorrsjö E., Talmud P., Lookene A., Olivecrona G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J. Biol. Chem. 2013; 288(47): 33997 — 40008.
Gracham M.J., Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013 May 24;112(11):1479-90.
Hommelberg P.P., Plat J. Sparks L.M., Schols A.M., van Essen A.L. Palmitate-induced skeletal muscle insulin resistance does not require NF-κB activation. Cell. Mol. Life. Sci. 2011; 68(7): 1215 — 25.
Mihas C., Kolovou G.D., Mikhailidis D.P, Kovar J., Lairon D, Nordestgaard B.G. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr. Vasc. Pharmacol. 2011; 9(3): 271 — 80.
Otokozawa S., Ai M., Diffenderfer M.R., Asztalos B.F., Tanaka A. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism. 2009; 58(11): 1536 — 42.
Mahalle N.P., Garg M.K., Kulkarni M.V., Naik S.S. Differences in traditional and non-traditional risk factors with special reference to nutritional factors in patients with coronary artery disease with or without diabetes mellitus. Indian. J. Endocrinol. Metab. 2013; 17(5): 844 — 50.
Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007; 25: 101 — 37.
Stroes E., Moulin P., Parhofer K.G., Rebours V., Löhr J.M., Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017; 23: 1 — 7.
Johansen C.T., Kathiresan S., Hegele R.A. Genetic determinants of plasma triglycerides. J. Lipid. Res. 2011; 52(2): 189 — 206.
Tani S., Matsumoto M., Nagao K., Hirayama A. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size. J. Cardiol. 2014; 63(1): 60 — 8.
Gaudet D., Brisson D., Tremblay K., Alexander V.J., Singleton W., Hughes S.G. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 2014; 371(23): 2200 — 6.
Pavlidis A.N., Kolovou G.D., Anagnostopoulou K.K., Petrou P.C., Cokkinos DVPostprandial metabolic heterogeneity in men with primary dyslipidaemia. Arch. Med. Sci. 2010; 6(6): 879 — 86.
Kolovou G.D., Anagnostopoulou K.K., Kostakou P.M., Bilianou H., Mikhailidis D.P. Primary and secondary hypertriglyceridaemia. Curr. Drug. Targets. 2009; 10(4): 336 — 43.
Ribalta J., Vallvé J.C., Girona J., Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr. Opin. Clin. Nutr. Metab. Care. 2003; 6(2): 177 — 87.
Ashavaid T.F., Kondkar A.A., Todur S.P., Dherai AJ., Morey J., Raghavan R. Lipid, lipoprotein, apolipoprotein and lipoprotein(a) levels: reference intervals in a healthy Indian population. J. Atheroscler. Thromb. 2005; 12(5): 251 — 9.
Sakurabayashi I., Saito Y., Kita T., Matsuzawa Y., Goto Y. Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin. Chim. Acta. 2001; 312(1-2): 87 — 95.
Шноль С.Э. Физико-химические факторы биологической эволюции. М.: Издательство «Наука»; 1979
O’Keefe J.H., Carter M.D., Lavie C.J. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin. Proc. 2009; 84(8): 741 — 57.
Kones R., Rumana U. Cardiovascular prevention: components, levels, early origins, and metrics. Hosp. Pract (1995). 2014; 42(3): 84 — 95.
Mihas C., Kolovou G.D., Mikhailidis D.P., Kovar J., Lairon D. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr. Vasc. Pharmacol. 2011; 9(3): 271 — 80.
Jumpertz R., Le D.S., Turnbaugh P.J., Trinidad C., Bogardus C., Gordon J.I., Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am. J. Clin. Nutr. 2011; 94(1): 58 — 65.